GV News & Events

The company said, "Building on previously announced initiatives, the Company plans to continue expanding its presence in international healthcare markets, including North America and Europe, through product commercialization, distribution partnerships, and healthcare service collaborations. Visionary intends to accelerate the commercialization of its RAMU anti-aging product line, targeting premium medical aesthetics and regenerative healthcare applications.The Company plans to further develop healthcare service platforms that combine medical aesthetics products, wellness services, and advanced biotechnology applications."

Visionary Holdings provided its 2026-2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets. The company said, "Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding into international healthcare markets, including North America and Europe, through product commercialization, healthcare service collaborations, and international distribution partnerships. Management believes that the global medical aesthetics and anti-aging industry continues to demonstrate strong long-term growth potential, driven by increasing consumer demand for advanced aesthetic treatments and regenerative healthcare solutions. Management believes that the period from 2026 through 2027 may represent an important stage in the Company's commercialization and international expansion within the healthcare and medical aesthetics sectors. Visionary expects that the commercialization of its RAMU anti-aging product line, part of the Company's medical aesthetics and regenerative healthcare portfolio, may become an important driver of revenue growth during this period. Based on current market expansion plans and distribution arrangements, management believes that RAMU-related product sales could potentially reach approximately $30M in annual sales, subject to market conditions, regulatory approvals, and operational execution. The Company also expects that these business segments may deliver relatively higher gross margins compared with certain legacy businesses, reflecting the premium positioning of medical aesthetics and anti-aging products within the global healthcare and wellness market. Revenue recognition and financial results will be determined in accordance with applicable accounting standards and the Company's financial reporting cycles."

Visionary Holdings, announced that its wholly owned subsidiary, Visionary Health Technology Group, announced the signing of a $12M exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company, alongside the Board-approved divestiture of its non-core education business.

On February 27, 2026, the Company's Board of Directors approved the transfer of 100% equity interests in Visionary Education Services & Management Inc., completing the planned exit from non-core legacy operations. With this divestiture, Visionary Holdings will operate as a streamlined biotechnology and healthcare-focused enterprise, allocating capital, technology and management resources exclusively toward: Anti-aging injectable products; Regenerative medical aesthetics; Biotechnology-driven healthcare innovation. The product is intended for aesthetic and wellness applications and is not intended to diagnose, treat, cure, or prevent any disease.